In-vitro Anti-trypanosomal and Cytotoxicity Evaluation of
                                        3-methyl-3,4-dihydroquinazolin-2(1H)-one Derivatives

Omobolanle J. Jesumoroti; Richard M. Beteck; Lesetja J. Legoabe

doi:10.1055/a-1349-1256

Drug Research, Table of Contents

Drug Res (Stuttg) 2021; 71(06): 335-340
DOI: 10.1055/a-1349-1256

Original Article

In-vitro Anti-trypanosomal and Cytotoxicity Evaluation of 3-methyl-3,4-dihydroquinazolin-2(1H)-one Derivatives

Authors

Omobolanle J. Jesumoroti

¹Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
Richard M. Beteck

¹Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
Lesetja J. Legoabe

¹Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa

Abstract

Sleeping sickness, caused by trypanosomes, is a debilitating, neglected tropical disease wherein current treatments suffer from several drawbacks such as toxicity, low activity, and poor pharmacokinetic properties, and hence the need for alternative treatment is apparent. To this effect, we screened in vitro a library of 2-quinazolinone derivatives for antitrypanosomal activity against T.b. brucei and cytotoxicity against HeLa cells. Seven compounds having no overt cytotoxicity against HeLa cells exhibited antitrypanosomal activity in the range of 0.093–45 µM were identified. The activity data suggests that the antitrypanosomal activity of this compound class is amenable to substituents at N1 and C6 positions. Compound 14 having a molecular weight of 238Da, ClogP value of 1 and a total polar surface area of 49 was identified as the most active, exhibiting an IC₅₀ value of 0.093 µM [Graphical Abstract].

Graphical Abstract.

Key words

sleeping sickness - 2-quinazolinone - hit - antitrypanosomal - cross screening

Full Text

References

References
1 Brun R, Schumacher R, Schmid C. et al. The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 2001; 6: 906-914
2 Barrett M, Burchmore R, Stich A. et al. The trypanosomiases. Lancet 2003; 362: 1469-1480
3 Beteck R, Legoabe L, Isaacs M. et al. In vitro anti-trypanosomal activities of indanone-based chalcones. Drug Research 2019; 69: 337-341
4 http://www.who.int/gho/neglected_diseases/human_african_trypanosomiasis/en/ Accessed on 06.11.2020
5 Kuepfer I, Hhary E, Allan M. et al. Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis 2011; 5: e968
6 Simarro P, Cecchi G, Franco J. et al. Estimating and mapping the population at risk of sleeping sickness. PLOS Neglected Tropical Diseases 2012; 6: e1859
7 Franco J, Simarro P, Diarra A. et al. Epidemiology of human African trypanosomiasis. Clin Epidemiol 2014; 6: 257-275
8 Kaiser M, Bray M, Cal M. et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrobial Agents and Chemotherapy 2011; 55: 5602-5608
9 MacLean L, Reiber H, Kennedy P. et al. Stage progression and neurological symptoms in Trypanosoma brucei rhodesience sleeping sickness: Role of the CNS inflammatory response. PLOS Negl Trop Dis 2012; 6: e1857
10 Kennedy PG. Human African trypanosomiasis of the CNS: Current issues and challenges. J Clin Invest 2004; 113: 496-504
11 Stich A, Abel P, Krishna S. Human African trypanosomiasis. BMJ 2002; 325: 203-206
12 Checchi F, Filipe J, Haydon D. et al. Estimates of the duration of the early and late stage of gambiense sleeping sickness. Infect Dis 2008; 8: 1-10
13 https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness) Accessed on 06:11:2020
14 Berninger M, Schmidt I, Ponte-Sucre A. et al. Novel lead compounds in pre-clinical development against African Sleeping Sickness. Med Chem Commun 2017; 8: 1872-1890
15 Babokhov P, Sanyaolu AO, Oyibo WA. et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health 2013; 107: 242-252
16 Mesu V, Kalonji B, Bardonneau W. et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial. The Lancet 2018; 391: 144-154
17 Deeks ED. Fexinidazole: first global approval. Drugs 2019; 79: 215-220
18 Lindner A, Lejon V, Chappuis F. et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: Substantial changes for clinical practice. The Lancet Infectious Diseases 2020; 20: e38-e46
19 Chappuis F. Oral fexinidazole for human African trypanosomiasis. The Lancet 2018; 391: 100-102
20 Steverding D. The development of drugs for treatment of sleeping sickness: A historical review. Parasit Vectors 2010; 3: 1-9
21 Marais L, Petzer A, Petzer JP. et al. The monoamine oxidase inhibition properties of C6‑ and N1‑substituted 3‑methyl‑3,4‑dihydroquinazolin‑2(1H)‑one derivatives. Molecular Diversity 2019; 24: 391-406
22 Burri C. Chemotherapy against human African trypanosomiasis; Is there a road to success?. Parasitol 2010; 137: 1987-1994
23 Babokhov P, Sanyaolu A, Oyibo A. et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathogens and Global Health 2013; 107: 242-252
24 Ahmed M, Youns M. Synthesis and Biological evaluation of a novel series of 6, 8-D ibromo-4 (3 H) quinazolinone derivatives as anticancer agents. Archiv der Pharmazie 2013; 346: 610-617
25 Field M, Horn D, Fairlamb A. et al. Antitrypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat Rev Microbiol 2017; 15: 217-231
26 Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. International Journal of Medicinal Chemistry 2014;
27 Noureldin N, Kothayer H, Lashine E. et al. Synthesis, anticonvulsant activity, and SAR study of novel 4-quinazolinone derivatives. Archiv der Pharmazie 2017; 350: 1600332
28 Mohamed M, Kamel M, Kassem E. et al. Synthesis, biological evaluation and molecular docking of quinazoline-4 (1H)-one derivatives as anti-inflammatory and analgesic agents. Acta Pol Pharm. Drug Res 2011; 68: 665-675
29 Zayed M, Hassan M. Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents. Saudi Pharmaceutical Journal 2014; 22: 157-162
30 Gatadi S, Lakshmi T, Nanduri S. 4 (3H)-Quinazolinone derivatives: Promising antibacterial drug leads. European Journal of Medicinal Chemistry 2019; 170: 157-172
31 Eissa A, El-Metwally A, El-Hashash M. et al. Synthesis and Biological Evaluation of Some New2-propyl-4 (3H)-Quinazolinone Derivatives as Anti-bacteria. Journal of the Korean Chemical Society 2008; 52: 328-337
32 Zhang J, Liu J, Ma Y. et al. One-pot synthesis and antifungal activity against plant pathogens of quinazolinone derivatives containing an amide moiety. Bioorganic Medicinal Chemistry Letters 2016; 26: 2273-2277
33 Ahmed M, Youns M. Synthesis and Biological Evaluation of a novel series of 6, 8-D ibromo-4 (3 H) quinazolinone derivatives as anticancer agents. Archiv der Pharmazie 2013; 346: 610-617
34 Birhan Y, Bekhit A, Hymete A. In vivo antimalarial evaluation of some 2, 3-disubstituted-4 (3 H)-quinazolinone derivatives. BMC Research Notes 2015; 8: 1-6
35 Wong WA. Weak spot in multiple protozoan parasites. J Structure 2017; 25: 1641-1643
36 Pandey R, Kumbhar B, Srivastava S. et al. Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: Binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation. Journal of Biomolecular Structure 2017; 35: 141-158
37 Scovill J, Blank E, Konnick E. et al. Antitrypanosomal activities of tryptanthrins. Antimicrobial Agents and Chemotherapy 2002; 882-883
38 Bukachi S, Wandibba S, Nyamongo I. The socio-economic burden of human African trypanosomiasis and the coping strategies of households in the South Western Kenya foci. PLoS Negl Trop Dis 2017; 11: e0006002
39 Marais L, Petzer A, Petzer JP. et al. The monoamine oxidase inhibition properties of C6-and N1-substituted 3-methyl-3,4-dihydroquinazolin-2(1H)-one derivatives. Molecular Diversity 2019; 24: 391-406
40 Devine W, Woodring JL, Swaminathan U. et al. Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery. J Med Chem 2015; 58: 5522-5537
41 Monti L, Wang S, Oukoloff K. et al. Brain-penetrant, triazolopyrimidine and phenylpyrimidine microtubule-stabilizers as potential leads to treat Human African Trypanosomiasis. ChemMedChem 2018; 13: 1751-1754
42 Beteck R, Legoabe L, Isaacs M. et al. Anti-Trypanosomal and antimalarial properties of tetralone derivatives and structurally related benzocycloalkanones. Medicina (Kaunas) 2019; 55: 206
43 Troeberg L, Chen X, Flaherty T. et al. Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei. Mol Med 2000; 6: 660-669
44 Veale C, Hoppe H. Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery. Med Chem Commun 2018; 9: 2037-2044 . DOI: 10.1039/C8MD00319J
45 Field M, Horn D, Fairlamb A. et al. Antitrypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol 2017; 15: 217-231
46 Beteck R, Isaacs M, Hoppe H. et al. Synthesis, in vitro cytotoxicity and trypanocidal evaluation of novel 1,3,6-substituted non-fluoroquinolones. S Afr J Chem 2018; 71: 188-195
47 Bollini M, Bruno A, Niño M. et al. Synthesis, 2D-QSAR studies and biological evaluation of quinazoline derivatives as potent anti-trypanosoma cruzi agents. J Medicinal Chemistry 2019; 15: 265-276

Supplementary Material

Supplementary Material (PDF) (opens in new window)